Published in TB and Outbreaks Week, February 15th, 2005
"A case-control study in Korea evaluated the protective effectiveness of the hantavirus vaccine. Point estimates showed increasing effectiveness with increasing numbers of doses received: 25% for one dose, 46% for two doses, and 75% for three doses," scientists writing in the journal Emerging Infectious Diseases report.
"All 95% confidence intervals overlapped zero; therefore, the findings could be due to chance," wrote Keeho Park at the National Cancer Center and collaborators in South Korea.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.